Author Correction: Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC.

Cai-Cun ZhouZiping WangMeili SunLejie CaoZhiyong MaRong WuYan YuWenxiu YaoSi SunJianhua ChenWu ZhuangJiuwei CuiXueqin ChenYou LuHong ShenChunhong HuJiwei LiuYunpeng LiuMengzhao WangXingya LiPing SunYongqian ShuJianying ZhouJingzhang LiKangsheng GuChangli WangHui ZhaoYiping ZhangChunling LiuJingru WangRumei ChenMengmeng QinHao WangJason Yang

Published in: Nature cancer (2024)

Keyphrases

phase iii
small cell lung cancer
open label
double blind
placebo controlled
clinical trial
phase ii
squamous cell carcinoma
locally advanced
advanced non small cell lung cancer
brain metastases
free survival
radiation therapy